Renaissance Technologies LLC Buys Shares of 51,254 Billiontoone, Inc. $BLLN

Renaissance Technologies LLC purchased a new position in shares of Billiontoone, Inc. (NASDAQ:BLLN) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 51,254 shares of the company’s stock, valued at approximately $4,046,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Adams Street Partners LLC acquired a new stake in shares of Billiontoone in the 4th quarter valued at $140,063,000. Baillie Gifford & Co. acquired a new position in Billiontoone during the fourth quarter worth $103,786,000. Price T Rowe Associates Inc. MD bought a new position in Billiontoone during the fourth quarter valued at about $39,717,000. JPMorgan Chase & Co. bought a new position in Billiontoone during the fourth quarter valued at about $32,078,000. Finally, Wasatch Advisors LP acquired a new stake in shares of Billiontoone in the first quarter worth about $29,179,000.

Insider Buying and Selling at Billiontoone

In other news, insider Shan Riku Sakakibara sold 4,000 shares of the stock in a transaction on Friday, July 31st. The shares were sold at an average price of $140.21, for a total value of $560,840.00. Following the completion of the transaction, the insider owned 200,000 shares in the company, valued at approximately $28,042,000. This represents a 1.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Bosch John Roderick Ten sold 1,416 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $120.00, for a total transaction of $169,920.00. Following the transaction, the senior vice president directly owned 33,552 shares of the company’s stock, valued at $4,026,240. The trade was a 4.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 202,049 shares of company stock worth $23,496,861. Corporate insiders own 50.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BLLN shares. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Guggenheim began coverage on Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 target price for the company. BTIG Research lowered their price target on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday. Wall Street Zen lowered shares of Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research note on Thursday. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.71.

Billiontoone Price Performance

Shares of NASDAQ:BLLN opened at $93.39 on Friday. The firm has a market capitalization of $4.30 billion and a PE ratio of 133.41. The company has a current ratio of 11.69, a quick ratio of 10.58 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $150.44. The business’s 50 day moving average is $116.49 and its 200-day moving average is $94.28.

Billiontoone (NASDAQ:BLLN) last issued its earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting analysts’ consensus estimates of $0.15. The business had revenue of $109.45 million during the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. Sell-side analysts predict that Billiontoone, Inc. will post 0.92 earnings per share for the current year.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.